<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950039</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001265</org_study_id>
    <secondary_id>7-13-CE-17</secondary_id>
    <nct_id>NCT01950039</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Betaine Supplementation</brief_title>
  <official_title>Bedside to Bench and Back: Cardiometabolic Effects of Betaine Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Betaine is important in cellular metabolic pathways. Few epidemiologic studies link betaine
      levels to diabetes and cardiovascular disease. Small human studies suggest benefit for
      non-alcoholic liver disease. In this study we will determine if administration of betaine
      improves metabolic measures, liver fat and/or endothelial function in humans with glucose
      intolerance who are overweight.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single site, prospective, randomized (1:1), double masked, placebo controlled
      trial to assess metabolic effects of betaine compared to placebo on glycemia and insulin
      sensitivity, liver fat and endothelial function.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>3 months</time_frame>
    <description>Glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic fat</measure>
    <time_frame>3 months</time_frame>
    <description>Magnetic resonance imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>3 months</time_frame>
    <description>Brachial artery reactivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Euglycemic hyperinsulinemic clamp</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obesity</condition>
  <condition>Dysglycemia</condition>
  <arm_group>
    <arm_group_label>Betaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaine</intervention_name>
    <description>Betaine or placebo administered orally in divided doses over 3 months.</description>
    <arm_group_label>Betaine</arm_group_label>
    <other_name>trimethyl glycine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally in divided doses over 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Men and women aged 21-65 years old;

          -  2) Dysglycemia/prediabetes is defined as impaired fasting glucose (≥100 mg/dl),
             impaired glucose tolerance (2 hour post 75 g oral glucose load 140-200 mg/dl) or HbA1c
             5.7-6.5%);

          -  3) Grade 1 obesity (BMI 27 to 36 kg/m2).

        Exclusion Criteria:

          -  1) cystathionine beta-synthase (CBS deficiency);

          -  2) Presence of liver disease other than NAFLD;

          -  3) Use of medications causing steatosis;

          -  4) Known alcohol consumption ≥ 2 drink per day;

          -  5) Use of medications known to cause insulin resistance;

          -  6) Use of weight loss drugs (or program) within 3 months of screening;

          -  7) Treatment with any experimental drug within the past 6 months;

          -  8) Subjects must be willing to abstain from use of phosphodiesterase type 5 (PDE-5)
             inhibitors;

          -  9) Pregnancy or lactation, and women of child bearing potential must use adequate
             contraception;

          -  10) Surgery within 30 days of screening;

          -  11) Heart disease defined as New York Heart Association Class III or IV cardiac status
             or hospitalization for congestive heart failure, unstable angina, myocardial
             infarction, cerebrovascular accident, transient ischemic attack or any
             revascularization within 6 months;

          -  12) Uncontrolled hypertension;

          -  13) eGFR &lt;60; 14) History of acquired immune deficiency syndrome;

          -  15) History of malignancy within 5 years;

          -  16) Hemoglobin &lt;12 g/dL (males), &lt;10 g/dL (females);

          -  17) Triglycerides (TG) &gt;500 mg/dL;

          -  18) Poor mental function or any other reason to expect patient difficulty in complying
             with study requirements;

          -  19) Metal clips or implants that preclude magnetic resonance imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Joslin Diabetes Center and Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Glucose Intolerance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

